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Abstract The NOTCH pathway is an evolutionarily con-
served signalling network, which is fundamental in regulating
developmental processes in invertebrates and vertebrates
(Gazave et al. in BMC Evol Biol 9:249, 2009). It regulates
self-renewal (Butler et al. in Cell Stem Cell 6:251–264, 2010),
differentiation (Auderset et al. in Curr Top Microbiol
Immunol 360:115–134, 2012), proliferation (VanDussen
et al. in Development 139:488–497, 2012) and apoptosis
(Cao et al. in APMIS 120:441–450, 2012) of diverse cell types
at various stages of their development. NOTCH signalling
governs cell-cell interactions and the outcome of such re-
sponses is highly context specific. This makes it impossible
to generalize about NOTCH functions as it stimulates survival
and differentiation of certain cell types, whereas inhibiting
these processes in others (Meier-Stiegen et al. in PLoS One
5:e11481, 2010). NOTCH was first identified in 1914 in
Drosophila and was named after the indentations (notches)
present in the wings of the mutant flies (Bigas et al. in Int J
Dev Biol 54:1175–1188, 2010). Homologs of NOTCH in ver-
tebrates were initially identified in Xenopus (Coffman et al. in
Science 249:1438–1441, 1990) and in humans NOTCH was
first identified in T-Acute Lymphoblastic Leukaemia (T-ALL)
(Ellisen et al. in Cell 66:649–61, 1991). NOTCH signalling is
integral in neurogenesis (Mead and Yutzey in Dev Dyn
241:376–389, 2012), myogenesis (Schuster-Gossler et al. in
Proc Natl Acad Sci U S A 104:537–542, 2007),
haematopoiesis (Bigas et al. in Int J Dev Biol 54:1175–1188,
2010), oogenesis (Xu and Gridley in Genet Res Int
2012:648207, 2012), differentiation of intestinal cells
(Okamoto et al. in Am J Physiol Gastrointest Liver Physiol
296:G23–35, 2009) and pancreatic cells (Apelqvist et al. in
Nature 400:877–881, 1999). The current review will focus on
NOTCH signalling in normal and malignant blood cell pro-
duction or haematopoiesis.
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NOTCH receptors and ligands
NOTCH proteins are single pass transmembrane receptors
that transduce extracellular signals into cells and mediate
cell-cell interactions (Artavanis-Tsakonas et al. 1999). The
mammalian NOTCH family consists of four NOTCH recep-
tors (NOTCH1-4), which share extensive structural homology
between its members (Fig. 1). Even across species as diverse
as from flies to humans the NOTCH receptors are highly
conserved (Schwanbeck and Just 2011). These receptors have
distinct and partially overlapping functions. The extracellular
domain (ECD) of NOTCH receptors consists of multiple
Epidermal Growth Factor (EGF) like repeats necessary for
ligand binding (Rebay et al. 1991). The intracellular domain
(ICD) consists of the RBP-Jkappa-associated module domain
(RAM), seven Ankyrin repeats, two nuclear localization sig-
nals, a transactivation domain and proline-glutamate-serine-
threonine-rich (PEST) domain (Allman et al. 2002).
The RAM and the Ankyrin repeats are essential for signal
transduction (Deregowski et al. 2006). The PEST domain
consists of several phosphorylation sites, which regulate the
NOTCH-ICD stability by ubiquitylation and are essential for
NOTCH protein turn over (Andersson et al. 2011). The RAM
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domain is the primary binding site for the CSL {Cp-binding
factor 1 (CBF-1)/recombination signal sequence-binding pro-
tein-Jκ (RBP-Jκ), Suppressor of hairless [Su (h)], and Lag-1}
(Iso et al. 2003) family of transcription factors, which modu-
late the transcription of NOTCH target genes like Hairy and
Enhancer of Split-1 (HES1) (Gordon et al. 2008).
There are five canonical NOTCH ligands in mammals be-
longing to Delta (Dll1, Dll3 and Dll4) and Jagged 1 (Jag 1 and
Jag 2) families (D’Souza et al. 2008). Like the NOTCH re-
ceptors, these ligands are also single pass transmembrane pro-
teins having multiple EGF-like repeats and cysteine rich se-
quences known as the Delta-Serrate-Lag2 (DSL) motif
(Lubman et al. 2007). The EGF-like repeats and the DSL
motifs on the ligands are required for them to bind and activate
the NOTCH receptors on the neighbouring cells (Shimizu
et al. 1999; Ohishi et al. 2003). These ligands have specificity
for different NOTCH receptors. In murine B cell develop-
ment, Dll1 functions as the main ligand for Notch2 whereas
in T cell development Dll4 interacts with Notch1
(Mohtashami et al. 2010).
The posttranslational modifications of NOTCH receptors and
NOTCH ligands are crucial in regulating NOTCH signalling.
For example, a glycosyltransferase called Fringe modifies the
EGF repeats of Notch receptors, which influences the proteolyt-
ic cleavage that release Notch-ICD (Moloney et al. 2000). The
direct binding of Fringe to Notch receptors also regulates the
specificity of Notch-ligand interactions (Okajima et al. 2003).
NOTCH signalling pathway
Within the cell, the NOTCH proteins undergo several proteo-
lytic processes giving rise to many cleaved forms of NOTCH.
Initially these receptors are cleaved by Furin proteases in the
trans-Golgi (Logeat et al. 1998) (Fig. 2). This is termed as S1
cleavage, which forms heterodimers of NOTCH composed of
NOTCH-ECD, a transmembrane and NOTCH-ICD. This
structure spans the plasmamembrane. The heterodimeric form
of NOTCH is suggested to be the predominant form of
NOTCH on the cell surface, however full length NOTCH
has also been detected. The absence of S1 cleavage sup-
pressed the formation of notches in the wings of Drosophila
indicating a direct correlation of loss of S1 cleavage with loss
of function of Notch (Lake et al. 2009).
The canonical NOTCH pathway is initiated by the binding
of the ligands expressed on the surface of the neighbouring
cells to the NOTCH-ECD. This results in the shedding of the
NOTCH-ECD and its endocytosis into the ligand-expressing
cell (Kopan and Ilagan 2009). The loss of the NOTCH-ECD
exposes an S2 cleavage site for ADAM metalloproteases
(Brou et al. 2000). Cleavage at the S2 site by ADAMs acti-
vates the receptor, which is still anchored to the plasma mem-
brane. The γ-secretase enzyme complex (Presenilin 1 and 2,
Nicastrin, APH1 and PEN2) cleaves the NOTCH receptor at
S3 and S4 sites and subsequently releases the active NOTCH-
ICD (De Strooper et al. 1999; Tien et al. 2009).
The two nuclear localization signals on the NOTCH-ICD
direct its translocation to the nucleus. Here, the NOTCH-ICD
binds to the CSL family of DNA binding proteins (RBP-J in
mammals) (Tani et al. 2001). The binding of NOTCH-ICD
removes the histone deacetylases (HDACs) and converts the
co-repressor CSL into a co-activator. The CSL and NOTCH-
ICD complex initiates transcription by recruiting chromatin
remodelling proteins histone acetyl transferases (HATs) (Lai
2002). This finally results in the transcription of the prototypic
NOTCH target gene HES, which functions as a major tran-
scriptional repressor (Iso et al. 2003).
There are many other NOTCH target genes including HEY
(subfamily of HES) (Monastirioti et al. 2010), c-MYC (Weng
et al. 2006), CD25 (Adler et al. 2003), GATA-3 (Hozumi et al.
2008), cyclin D1 (Cohen et al. 2010), p21 (Guo et al. 2009),
HOXA5, HOXA9 and HOXA10 (Weerkamp et al. 2006). The
genes targeted by NOTCH either directly or indirectly are
highly context specific.
The non-canonical pathway is CSL independent and can
signal without conventional ligand interactions (Andersen
et al. 2012). Some of the non-canonical NOTCH ligands in-
clude CCN3, microfibril-associated glycoprotein family
(MAGP-1, MAGP-2), F3/Contactin 1, NB3/Contactin 6,
which are involved in neural adhesion (D’Souza et al. 2008).
One of the major effectors of the non-canonical NOTCH sig-
naling is the Wnt/β-Catenin pathway (Hayward et al. 2005).
Most of the non-canonical NOTCH interactions are observed
in embryonic cells and in stem/progenitor cells, which implies
the role of NOTCH signalling in undifferentiated cell popula-
tions (Andersen et al. 2012).
Fig. 1 NOTCH receptors. The mammalian NOTCH family has four
members NOTCH1-4; all consist of extracellular and intracellular
domains. The extracellular domain 29–36 Epidermal growth factor
(EGF) like repeats followed by three Lin-NOTCH repeats (LNR). The
intracellular domain has the RBP-J-associated molecule (RAM) domain,
six ankyrin repeats (ANK), nuclear localization sequences (NLS), a
transactivation domain (TAD) required for activating transcription and a
proline-, glutamate-, serine- and threonine-rich (PEST) domain which
regulates NOTCH degradation. NOTCH1 and NOTCH2 are
structurally similar, NOTCH3 and NOTCH4 are smaller proteins as
they have fewer EGF repeats and lack TAD
6 S. Suresh, A.E. Irvine
From this brief introduction it is evident that the field of
NOTCH signaling is still young andmuch remains to be learnt
about this complex pathway. Nevertheless, given the key role
of NOTCH in co-operating with multiple signaling networks,
particularly in stem cells, it is clear that modulation of this
system may offer new therapeutic strategies in a variety of
disease states. In this reviewwewill focus on the development
of such knowledge in blood stem cells and the application of
this in Leukaemia.
NOTCH in haematopoiesis
Blood cell production, haematopoiesis is the result of a tightly
regulated balance of self-renewal and differentiation of
haematopoietic stem cells (HSCs) (Fig. 3). During
haematopoiesis NOTCH proteins are expressed at different
stages of development. The activation of NOTCH in
haematopoietic cells occurs during their interaction with other
haematopoietic cells as well as with bone marrow stromal
cells expressing NOTCH ligands (Bigas et al. 2010). Early
studies have demonstrated the expression of NOTCH1 and
NOTCH2 in the CD34+Lin− precursors in the human bone
marrow (Kojika and Griffin 2001; Ohishi et al. 2003).
Stromal cells express NOTCH ligands Jagged1, Dll1 and
Dll4 (Fernandez-Sanchez et al. 2011). Expression of all these
ligands are observed in the thymus, which indicates the im-
portance of NOTCH signaling in T cell development (de
Pooter et al. 2006). Culturing murine Lin−Sca-1+c-kit+
(LSK) cells in the presence of immobilized Notch ligand
Delta 1 reduced myeloid differentiation.When combined with
IL-7, Notch signalling promoted early T- cell development
whereas use of GM-CSF and Notch resulted in myeloid dif-
ferentiation (Varnum-Finney et al. 2003). Under in vitro con-
ditions endothelial cell production of NOTCH ligands was
able to promote the self-renewal capacity of HSCs (Butler
et al. 2010).
In the myeloid lineage, increased expression of NOTCH1
and NOTCH2 is reported in granulocytes (Ohishi et al. 2003).
The expression of NOTCH1 decreases upon maturation of
erythroid progenitors into erythroid cells (Walker et al.
2001). In Notch1 deficient mice, HSC generation was severe-
ly impaired with no HSC activity detected in the para-aortic
splanchnopleura and in the yolk sac (Kumano et al. 2003). In
Fig. 2 NOTCH signaling pathway. In the golgi apparatus the Notch
receptor undergoes proteolytic processing, which is S1 cleavage
mediated by Furin proteases. The receptor is transported to the cell
surface membrane. The extracellular domain of the Notch receptor
(Notch-ECD) in the signalling cell binds with the Notch ligands (Delta,
Jagged, Serrate) expressed by the adjacent cell. This induces the second
proteolytic step, S2 cleavage by ADAM metalloproteases, and leads to
the endocytosis of the Notch-ECD into the ligand-expressing cell. This is
followed by the release of the Notch intracellular domain (Notch-ICD)
with a tethered membrane. This is now a substrate for the gamma
secretase enzyme complex, which cleaves the Notch-ICD from the
membrane by S3 and S4 cleavages. The resulting active Notch-ICD
translocates to the nucleus and interacts with the CSL protein. In the
absence of Notch-ICD, the CSL is bound to co-repressor. Binding of
Notch-ICD with CSL results in the formation of an active complex with
MAML and other co-activators and leads to the transcription of Notch
targets HES and HEY
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mouse embryos, activation of Gata2 by Notch1/Rbp-j is es-
sential for the onset of definitive haematopoiesis. For Notch1
to regulate Gata2 in the dorsal aorta, it has to be activated by
Jagged-1 ligand, which suggests the importance of ligand-
Notch specificity during haematopoiesis (Robert-Moreno
et al. 2005). In transgenic mice, Notch1 signalling was active
in HSCs and decreased upon their differentiation. The inhibi-
tion of Notch1 signalling enhanced the differentiation of
HSCs in vitro but depleted the HSCs in vivo. It was shown
in this study that Notch1 cooperates with Wnt signalling to
maintain HSCs in undifferentiated state (Duncan et al. 2005).
In contrast, another study that addressed the loss of function of
canonical Notch signalling in murine adult HSCs ruled out
any physiological roles for this pathway in these cells.
However, this study did not address the effects of non-
canonical NOTCH signalling on HSCs (Maillard et al.
2008). Therefore to fully understand the necessity of
NOTCH signalling, it is essential to investigate the effects of
non-canonical NOTCH signalling on HSCs.
The role of NOTCH signalling in haematopoiesis is com-
plex. In murine LSK haematopoietic cells, constitutive
Notch1 signalling (by forced expression of Notch1-ICD),
gave rise to pluripotent, cytokine dependent HSCs. This study
showed overexpression of active Notch1 having the ability to
immortalize HSCs, which could lead to neoplasia (Varnum-
Finney et al. 2000). Further, Notch1 activation inhibited the
differentiation of murine Sca1+lin− bone marrow cells, which
maintained these cells in their ‘stemness’ rather than entering
into the progenitor pool. Also, active Notch signalling in these
cells determined their lineage commitment by favouring
lymphopoiesis at the expense of myeloid cell production
(Stier et al. 2002). In line with these observations, the retrovi-
ral expression of Hes1 in murine HSCs prolonged their self-
renewal capacity ex vivo (Kunisato et al. 2003).
Notch ligands have promising clinical applications.
A d d i t i o n o f J a g g e d - 1 l i g a n d t o t h e h um a n
CD34+CD38−Lin− cord blood cells expanded the progenitor
cells and contributed to the short-term reconstitution in mice
(Butler et al. 2010). Similar results were obtained with treating
murine bone marrow LSK cells with Dll1 ligand (Delaney
et al. 2005). Notch ligand Delta 1 was able to expand cord
blood progenitors and when used in a clinical setting resulted
in rapid haematopoietic recovery (Delaney et al. 2010). In
these studies the haematopoietic stem/progenitor cells were
exposed to high doses of Notch ligands resulting in enhanced
Notch signalling, which could potentially decrease the effect
induced by other haematopoietic signalling pathways that ei-
ther co-operate or are independent of NOTCH signalling. Care
should be taken in interpretation of in vitro experiments where
cells are exposed to high NOTCH signalling as this does not
represent its effects in steady state conditions. For example,
Benveniste et al., found that human HSCs are expanded by
NOTCH signaling in vitro but were not required for their
maintenance or self-renewal in vivo (Benveniste et al. 2014).
Much of our understanding about NOTCH signalling in
haematopoiesis comes from studies focused on the
NOTCH1 receptor, the most potent of four receptors in acti-
vating transcription. Few studies have addressed the impor-
tance of other members of NOTCH family. In murine quies-
cent LSK cells, treatment with Dll1 or Jagged-1 activated
Notch-2 and inhibited myeloid differentiation. Notch-2 acti-
vation modulated bone marrow stress recovery in mice receiv-
ing 5-Flurouracil by enhancing the rate of production of multi-
potential progenitors with both short-term and long-term
repopulating potential (Varnum-Finney et al. 2011). The ex-
pression of NOTCH4 in human bone marrow CD34+CD38−
primitive progenitor cells is high (along with high NOTCH1)
compared to the mature progenitor fraction CD34+CD38+.
Fig. 3 Haematopoiesis. Blood
cell production is maintained by a
small population of stem cells
found in the bone marrow; these
cells have the ability to self-renew
or differentiate. Cells then
differentiate to multi-potential
and lineage committed
progenitors; these cells can’t be
distinguished morphologically,
only by the use of clonogenic
assays. The final stage of
differentiation is when the cells
develop their characteristic
morphology and are released into
the circulation
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Constitutively active NOTCH4 decreased monocytic and ery-
throid differentiation. Human cord blood cells with transduced
NOTCH4-ICD showed higher engraftment potential in the
bone marrow of immune-deficient mice. Active NOTCH4
favours differentiation in to lymphoid lineage similar to
NOTCH1 (Vercauteren and Sutherland 2004).
NOTCH in leukaemia
The constitutive activation of NOTCH signalling has been
linked to excessive cell proliferation and arrested differentia-
tion contributing to the development of cancer (Rosati et al.
2009). Given the importance of NOTCH signalling in
haematopoiesis, it is not surprising that defective NOTCH
signalling is involved in leukaemic transformation.
Activating mutations of NOTCH1 are observed in nearly
50 % of T-ALL and 30 % of Adult-T cell Leukaemia (ATL)
patients (Weng et al. 2004). The mutations cause ligand inde-
pendent activation of NOTCH1 receptors and enhanced sta-
bility of the NOTCH1-ICD. This subsequently leads to the
increased proliferation and survival of leukaemic cells (Staal
and Langerak 2008). A role for NOTCH3 in leukaemia was
reported in studies using transgenic mice overexpressing
NOTCH3-ICD, which gave rise to T cell leukaemia
(Bellavia et al. 2002). In T-ALL, NOTCH3 has been shown
to cooperate with MAPK pathway resulting in leukaemic sur-
vival (Masiero et al. 2011).
Gain of functionmutations ofNOTCH1 have been reported
in Chronic Lymphocytic Leukaemia (CLL) (Fabbri et al.
2011). In CLL, NOTCH1 mutations impair FBW7 E3 ligase
induced degradation of NOTCH1. These mutations were seen
in patients with aggressive CLL refractory to chemotherapy
(O’Neil et al. 2007). In CLL, NOTCH1 mutations were sug-
gestive of poor prognosis, but whether they are causative or
drive the disease is not known (Rossi et al. 2012).
Activating NOTCH2 mutations are observed in ~8 % of
diffuse large B-cell lymphomas (Lee et al. 2009) and in 5 %
of marginal zone lymphomas (Troen et al. 2008). The in vitro
studies showed mutated NOTCH2 receptors having higher
activity (Lee et al. 2009). There are currently no reports of
NOTCH4 involvement in leukaemia.
NOTCH in myeloid leukaemia
Unlike its established role in lymphoid leukaemias, there are
conflicting reports regarding NOTCH signalling in myeloid
leukaemia. This may reflect both disease heterogeneity and
variation in experimental design. For example, the choice of
experimental models differ between the research groups rang-
ing from the use of immortalized leukaemic cell lines, primary
cells from mice or humans and in vivo studies using
leukaemic mouse models of different strains.
Several studies have attempted the expression profiling of
Notch receptors and the Notch downstream target genes in
myeloid leukaemias. One study reported AML patients hav-
ing highNOTCH1 gene expression in peripheral blood mono-
cytes whereas HES1 levels were low suggesting inactive
NOTCH signalling (Chiaramonte et al. 2005). It is also to be
noted that this group reported higher JAGGED1 expression in
AML samples than in T-ALL. Tohda et al. reported the ex-
pression of NOTCH1 receptor protein in 40 % of AML sam-
ples, but the activation of NOTCH1 targets was not assessed
in this study (Tohda and Nara 2001). In a later study by the
same group primary AML cells isolated from peripheral blood
were treated with immobilized NOTCH ligands Jagged1 and
Delta1; cellular responses to these ligands range from in-
creased proliferation to suppressed proliferation (Tohda et al.
2005). Since the culture conditions were the same for all the
samples, the reason for such differences could be the hetero-
geneity of the AML samples.
Whole genome microarray analysis of leukaemia initiating
c e l l s c omp r i s i n g t h e L i n −CD34 +CD38 − a n d
Lin−CD34+CD38+ fromAML patients showed reduced levels
of NOTCH target gene expression in comparison with the
CD34+ bone marrow cells from normal donors. The CD34+
cells isolated from cord blood AML samples had less HES1
mRNA expression. In these samples the NOTCH1 levels were
low but NOTCH2 mRNA levels were surprisingly high. The
authors also report decreased NOTCH1 and NOTCH targets
and increased NOTCH2 in the leukaemia initiating HSC pop-
ulation in an MLL-AF9 AML mouse model. Inducible acti-
vation of NOTCH1-ICD suppressed the disease phenotype
and was associated with a decrease in the leukaemic initiating
cell population. Similarly the MLL-AF9 AML mice with in-
duction of NOTCH2-ICD survived while the control
leukaemic mice did not. Treatment of primary AML cells with
Notch ligand Dll4 induced differentiation to a macrophage
lineage followed by apoptotic clearance (Lobry et al. 2013).
In another microarray gene expression profiling study CD34+
bone marrow cells from AML patients had NOTCH1 and
NOTCH2 expression similar to the normal donor samples,
however the levels of NOTCH targets HES1 and DELTEX1
were lower in AML cells indicating reduced NOTCH signal-
ling despite the expression of NOTCH receptors (Kannan
et al. 2013). The corresponding protein expression analysis
revealed NOTCH2 expressed at higher level, which was in
agreement with the report of Lobry et al. (Lobry et al. 2013).
Activation of the NOTCH signalling pathway by induced ex-
pression of the NOTCH1-ICD inhibited the proliferation of
several AML cell lines and was attributed to the associated
increase in HES1 whereas inhibition of the overall NOTCH
signalling had no effect on these cell lines. An interesting
observation made in this report is that the active intracellular
NOTCH signalling in haematopoiesis 9
domains for each of the four NOTCH receptors were anti-
proliferative with varying effect indicating that the growth
inhibition is most likely mediated by a downstream compo-
nent common to the NOTCH receptors. Accordingly, it was
found that HES1 was induced by all NOTCH receptors and its
activation was sufficient to induce growth arrest, which was
accompanied by an increase in p53 and reduced anti-apoptotic
BCL2 protein. Treatment of human primary AML cells with a
NOTCH agonist peptide induced significant apoptosis
(Kannan et al. 2013). These findings expand our understand-
ing about the relative contributions of the four NOTCH recep-
tors and the downstream signals in myeloid leukaemia and
should pave the way for experiments designed to take these
findings to clinical applications.
Activating mutations of NOTCH1 have been postulated to
be restricted to T-ALL and are rare in myeloid leukaemias
(Palomero et al. 2006). However, a recent genome wide alter-
nate splicing study reported NOTCH2 along with FLT3 as the
most aberrantly spliced genes detected in the majority of the
AML patients (Adamia et al. 2014). The NOTCH2 variants
had a specific pattern of expression during the different stages
of AML with 79 % AML patients expressing the variant
NOTCH2-Va, during remission 40 % of AML patients were
negative for NOTCH2-Va and during relapse 80 % of AML
patients expressed this variant. High NOTCH2-Va expression
was also associated with poor clinical outcome in the interme-
diate cytogenetic risk AML groups. The CD34+ bone marrow
cells of AML patients with high expression ofNOTCH2 splice
variant had decreased mRNA expression of NOTCH targets
HES1, HEY1 and DTX1 compared with CD34+ AML cells
expressing full length NOTCH2. This suggests that the ex-
pression of NOTCH2 splice variants have oncogenic potential
and results in the inactivation of NOTCH pathway and this
process might be contributing to AML pathology (Adamia
et al. 2014). In contrast with the above observations, there
have been reports of elevated expression of NOTCH1, Dll4
and HES1 transcripts and corresponding increase in
NOTCH1-ICD, Dll4 and HES1 protein in AML patients.
Also, AML patients with highest NOTCH1 expression were
reported to have poor overall survival (Zhang et al. 2013).
In Chronic Myeloid Leukaemia (CML), inhibition of
NOTCH1 expression in K562 cells induced erythroid matu-
ration of these cells (Lam et al. 2000). K562 cells have been
reported to be resistant to NOTCH1 inhibition with gamma
secretase inhibitor (GSI) (Moellering et al. 2009; Ren and
Cowell 2011). However, when K562 cells were induced to
express the non-canonical NOTCH ligand CCN3, they were
responsive to GSI inhibition, which resulted in reduced colony
formation. Besides K562 cells, other CML cell line models
like KCL22 and LAMAwere sensitive to GSI when used in
combination with either recombinant CCN3 or imatinib.
BCR-ABL knockdown in all these cell lines reduced
NOTCH1 signalling and inhibition of NOTCH was anti-
proliferative suggesting NOTCH1 to have an oncogenic role
in CML (Suresh et al. 2013). Similarly, in a transgenic CML
mouse model overexpressing Bcr-Abl, activation of Notch1
was observed. In this model, activated Notch1-ICD was
shown to cooperate with Bcr-Abl contributing to CML blast
crisis (Mizuno et al. 2008). Contrary to these observations,
inactivation of Notch1 in mouse HSCs induced chronic
myelomonocytic leukaemia (CMML) and Notch1 here has
been suggested to have tumour suppressor roles (Klinakis
et al. 2011). In this study, conditional knockdown of
Notch1/2/3 genes in mouse models induced CMML like dis-
ease and introduction of Notch1 or Notch2 could rescue the
disease phenotype. This study also reported Notch1-ICD ex-
pression in murine leukaemia initiating cells upregulating
HES1 levels, which led to the repression of myeloid expan-
sion. However, HES1 has been previously reported to cause
CML blast crisis transformation in mice (Nakahara et al.
2010). These different outcomes of defective NOTCH1 sig-
nalling across myeloid leukaemias show the complexity of
this signalling pathway. This reflects the problem of general-
izing about NOTCH1 signalling in haematopoiesis.
Conclusion
There is substantial evidence establishing the role of NOTCH
in haematopoiesis and leukaemia. Since constitutively active
NOTCH-ICD contributes to cancer progression in many
cases, several small molecule inhibitors that either block the
function of gamma secretase complex or monoclonal antibod-
ies to NOTCH receptors/ligands are being developed and
many of these compounds are currently in clinical trials. In
laboratory settings GSI has beenwidely used to investigate the
effects of NOTCH inhibition. However, the first Phase I clin-
ical trial for the GSI MK-0752 (developed by Merck,
Whitehouse Station, NJ, USA) for relapsed or refractory T-
ALL patients and advanced breast cancers was met with se-
vere toxicity (Takebe et al. 2014). GSI has a very broad spec-
trum of action, it inhibits signalling of all four NOTCH recep-
tors and it has other substrates like CD44 (Murakami et al.
2003), ERBB4 (Vidal et al. 2005) and Cadherins (Marambaud
et al. 2002). Monoclonal antibodies to NOTCH ligands (Tran
et al. 2013) and receptors are under development to improve
target specificity (Wu et al. 2010). Phase I studies with
demcizumab; a humanized antibody to Dll4 (OMP-21M18,
OncoMed Pharmaceuticals, CA, USA) and OMP-59R5 and
OPM-52M51 (monoclonal antibodies to NOTCH 2 and
NOTCH 3 respectively) are currently underway (Takebe
et al. 2014).
The role of NOTCH as a potential target for cancer therapy
is a new field of research, as the initial observation of its
importance in cancer was known only in 2004 (Weng et al.
2004). As discussed in this review, the significance of
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NOTCH in myeloid leukaemias is not well defined unlike its
oncogenic potential in T-ALL. Therefore it is too early to
know how the NOTCH signalling pathway could be therapeu-
tically useful in myeloid leukaemias. Currently, targeting
NOTCH has tremendous potential in fine-tuning a signalling
pathway that cooperates with multiple signalling networks.
However, leukaemias being stem cell disorders, it is essential
to understand how NOTCH inhibition affects normal stem
cells while investigating NOTCH based anticancer therapies.
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